Ligelizumab improves angioedema, disease severity and quality-of-life in patients with chronic spontaneous urticaria

Ligelizumab improves angioedema, disease severity and quality-of-life in patients with chronic spontaneous urticaria

Background: Disease burden is particularly high in Chronic Spontaneous Urticaria (CSU) patients with angioedema, and patients whose signs and symptoms are inadequately controlled by H1-antihistamines need new treatment options. Here we report an exploratory analysis, from the ligelizumab Phase 2b st...

Full description

Bibliographic Details
Main Authors: Martin Metz, MD, Jonathan A. Bernstein, MD, Ana M. Giménez-Arnau, MD, PhD, Michihiro Hide, MD, PhD, Marcus Maurer, MD, Karl Sitz, MD, Weily Soong, MD, Gordon Sussman, MD, Eva Hua, MSc, Avantika Barve, PhD, Nathalie Barbier, MSc, Maria-Magdalena Balp, MD, Thomas Severin, MD
Format: Article
Language:English
Published: Elsevier 2022-11-01
Series:World Allergy Organization Journal
Subjects:
Angioedema
Chronic spontaneous urticaria
Dermatology life quality index
IgE
Ligelizumab
Online Access:http://www.sciencedirect.com/science/article/pii/S1939455122000928

Internet

http://www.sciencedirect.com/science/article/pii/S1939455122000928

Similar Items